(19)
(11) EP 4 580 642 A2

(12)

(88) Date of publication A3:
25.04.2024

(43) Date of publication:
09.07.2025 Bulletin 2025/28

(21) Application number: 23861474.7

(22) Date of filing: 29.08.2023
(51) International Patent Classification (IPC): 
A61K 35/17(2025.01)
A61P 31/12(2006.01)
C07K 14/705(2006.01)
C07K 16/28(2006.01)
A61P 35/00(2006.01)
C07K 16/30(2006.01)
C07K 14/725(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 2330/51; C12N 15/111; C12N 15/113; C12N 2310/14
(86) International application number:
PCT/US2023/073035
(87) International publication number:
WO 2024/050325 (07.03.2024 Gazette 2024/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 01.09.2022 US 202263403219 P

(71) Applicant: SRI International
Menlo Park, CA 94025 (US)

(72) Inventors:
  • BHATNAGAR, Parijat
    Menlo Park, California 94025-3493 (US)
  • RADHAKRISHNAN, Harikrishnan
    Menlo Park, California 94025-3493 (US)

(74) Representative: D Young & Co LLP 
3 Noble Street
London EC2V 7BQ
London EC2V 7BQ (GB)

   


(54) GENETICALLY ENGINEERED CD4 T-CELLS FOR IN SITU SYNTHESIS OF PROTEINS